TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
In a report released yesterday, Yaron Werber from TD Cowen maintained a Buy rating on Foghorn Therapeutics (FHTX – Research Report). The ...
TD Cowen breaks down what investors should watch for in the presidential election
Chris Krueger, TD Cowen managing director, joins 'Power Lunch' to discuss the markets could respond depending on the election ...
TD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TD Cowen analyst Daniel Brennan maintained a Hold rating on Myriad Genetics (MYGN – Research Report) today and set a price target of ...
Devon Energy Q3 Earnings Preview: All eyes on impact of Grayson Mill purchase
Devon Energy ( NYSE: DVN) is scheduled to announce Q3 earnings results on Tuesday, November 5th, after market close. The company last generated better-than-expected Q2 adjusted earnings and raised its ...
Berkshire EPS misses estimates as insurance losses, mixed results weigh on Q3
Berkshire Hathaway's third-quarter results fell short of analyst expectations, with EPS underperforming consensus projections ...